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VDACMitochondria, central to basic life functions due to their generation of cellular energy, also serve as the venue
for cellular decisions leading to apoptosis. A key protein in mitochondria-mediated apoptosis is the voltage-
dependent anion channel (VDAC), which also mediates the exchange of metabolites and energy between the
cytosol and the mitochondria. In this study, the functions played by the N-terminal region of VDAC1 and by
VDAC1 oligomerization in the release of cytochrome c, Smac/Diablo and apoptosis-inducing factor (AIF) and
subsequent apoptosis were addressed. We demonstrate that cells undergoing apoptosis induced by STS or
cisplatin and expressing N-terminally truncated VDAC1 do not release cytochrome c, Smac/Diablo or AIF.
Ruthenium red (RuR), AzRu, DIDS and hexokinase-I (HK-I), all known to interact with VDAC, inhibited the
release of cytochrome c, Smac/Diablo and AIF, while RuR-mediated inhibition was not observed in cells
expressing RuR-insensitive E72Q-VDAC1. These ﬁndings suggest that VDAC1 is involved in the release of not
only cytochrome c but also of Smac/Diablo and AIF. We also demonstrate that apoptosis induction is
associated with VDAC oligomerization, as revealed by chemical cross-linking and monitoring in living cells
using Bioluminescence Resonance Energy Transfer. Apoptosis induction by STS, H2O2 or selenite augmented
the formation of VDAC oligomers several fold. The results show VDAC1 to be a component of the apoptosis
machinery and offer new insight into the functions of VDAC1 oligomerization in apoptosis and of the VDAC1
N-terminal domain in the release of apoptogenic proteins as well as into regulation of VDAC by anti-
apoptotic proteins, such as HK and Bcl2.denine nucleotide translocase;
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Located in the outer mitochondrial membrane (OMM), the
voltage-dependent anion channel (VDAC) not only assumes a crucial
position in the cell, controlling metabolic cross-talk between the
mitochondrion and the rest of the cell, thus regulating the metabolic
and energetic functions of the mitochondria [1,2], but is also a key
player inmitochondria-mediated apoptosis [3,4]. Apoptosis is a highly
regulated process that plays a protective role in physiological con-
ditions, with dysregulation of apoptosis having been implicated in
many diseases. During apoptosis, coordinated morphological and bio-
chemical changes occur within the nucleus, cytoplasm, organelles andthe plasma membrane [5]. Mitochondria-mediated apoptosis can
be triggered by both external and internal stimuli and results in
the release of a large number of apoptogenic proteins from the
intermembrane space (IMS) to the cytosol [6], including cytochrome c
(Cyto c) [7], second mitochondrial activator of caspases (Smac/
Diablo) [8] and HtrA2/Omi [9]. Smac/Diablo and Omi/HtrA2 [10]
potentiate caspase activation by binding inhibitor of apoptosis
proteins (IAPs) and blocking their caspase inhibitory activities [11].
Other proteins released include apoptosis-inducing factor (AIF) and
endonuclease G (EndoG). AIF induces chromatin condensation and
large-scale DNA fragmentation (50 kbp) when released into the
cytosol [12]. Since these mitochondrial apoptogenic proteins are
conﬁned within the IMS, their release, following an apoptotic stimu-
lus, requires permeabilization of the OMM [13–15]. Hence, VDAC,
acting as an OMM channel, might mediate the release of mitochon-
drial proteins, such as Cyto c and AIF. Indeed, VDAC has been impli-
cated in apoptosis-relevant events, due to it serving as the target
for members of the pro- and anti-apoptotic Bcl2-family of proteins
[16–18] and due to its function in the release of apoptotic proteins
from the IMS [3,4]. Recently, we have shown that cells expressing N-
terminally truncated VDAC1 do not release cytochrome c and are
resistant to apoptosis [3].
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should consider the molecular sizes of the released proteins (12 to
100 kDa). The inner diameter of the VDAC pore is 1.5 nm [19], large
enough to accommodate nucleotides and small molecules but too
small to allow the passage of a folded protein, like Cyto c (diameter
3.1 nm) [20]. The protein-conducting channel could thus reside with-
in a VDAC1 homo-oligomer or hetero-oligomers containing VDAC1
and pro-apoptotic proteins [2,3,21,22]. We have demonstrated that
VDAC can exist as oligomers and proposed that oligomeric VDAC1
mediates the release of Cyto c [2,3,22–24]. Atomic Force Microscopy
(AFM) imaging allowed revealed the supra-molecular organization of
VDAC in the outer membrane of mitochondria isolated from yeast or
potato tubes [25,26]. No such studies are available for mammalian
mitochondrial VDAC. Meanwhile, NMR-based studies suggest the
existence of VDAC1 dimers [19,27,28], while recent analysis of crystal
packing in mVDAC1 [29] revealed a strong anti-parallel dimer that
further assembled into hexamers, mimicking the native six pore
packing observed in EM [30] and AFM images of the OMM [25,26].
The most convincing ﬁnding connecting VDAC oligomerization to
apoptosis to date was presented in our recent study demonstrating
that apoptosis induction by various stimuli, including cisplatin, eto-
poside, staurosporine, As2O3, curcumin, UV irradiation and H2O2, is
accompanied by an up to 20-fold increase in VDAC oligomerization
[23]. Thus, substantial evidence showing the formation of higher
order VDAC-containing complexes and the enhancement of supra-
molecular assembly of VDAC in cultured cells upon apoptosis in-
duction support the involvement of VDAC oligomerization in Cyto c
release and, thus, in apoptosis.
Alternative models for the release of Cyto c and AIF also exist. These
include rupture of theOMMas a consequence ofmitochondrial swelling
after the opening of the permeability transition pore (PTP) [31], or Bax/
Bak-mediated induction of a selective process of OMMpermeabilization
through the formationof channels orpores allowing the selective release
of pro-apoptotic proteins soluble in the IMS, such as Cyto c [32,33].
Indeed, accumulating evidence suggests that multiple pathways and
mechanisms of Cyto c release can co-exist within a single model of cell
death, depending on the cell type and the nature of the stimulus [34,35].
Despite the fact that numerous studies suggest the existence of
multimeric VDAC complexes [2,3,16,22,25,26], visualization and
monitoring of the dynamics of complex assembly remain a challenge.
Recently, we have demonstrated that Cyto c release and apoptosis are
coupled to VDAC oligomerization, as visualized using chemical cross-
linking and, in living cells, using Bioluminescence Resonance Energy
Transfer (BRET2) [23,36]. In this study, we further explored the
relationship between VDAC oligomerization, Cyto c and AIF release,
and apoptosis, as well as the function of the N-terminal region of
VDAC1 in the release of apoptotic proteins, apoptosis induction and
regulation by anti-apoptotic proteins.
2. Materials and methods
2.1. Materials
Poly-D-lysine (PDL), tetracycline, staurosporine (STS) and sodium
selenite, 4,4'-diisothiocyano stilbene-2,2'-disulfonic acid (DIDS),
H2O2, 1,5-diﬂuoro-2,4-dinitrobenzene (DFDNB) and cytochalasin B
were purchased from Sigma (St. Louis, MO). EGS (ethylene glycol bis
[succinimidylsuccinate]) was obtained from Pierce Chemical (Rock-
ford, IL). An annexin V-FITC kit was purchased from Bender
MedSystem (Burlingame, CA). Metefectene was purchased from
Biotex (Munich, Germany). DMEM (Dulbecco's Modiﬁed Eagle
Medium) growth media and the supplements, fetal calf serum
(FCS), L-glutamine and penicillin-streptomycin were purchased
from Biological Industries (Beit Haemek, Israel). Blasticidin was
purchased from InvivoGen (San Diego, CA). Digitonin came from
Calbiochem-Novobiochem (Nottingham, UK). Coelentrazine (Deep-BlueC, DBC) was obtained from Bioline (Taunton, MA). Monoclonal
anti-VDAC antibodies directed against the N-terminal region of 31HL
human porin came from Calbiochem-Novobiochem (Nottingham,
UK). Monoclonal anti-actin antibodies were obtained from MP
Biomedicals (Aurora, Ohio), while anti-Smac (2D12) antibodies
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Polyclonal anti-AIF antibodies raised to recombinant AIF amino acid
residues 121–613 came from R&D Systems (Minneapolis, MN).
Monoclonal anti-Cyto c antibodies were obtained from BD Biosciences
Pharmingen (San Jose, CA). Alexa Fluor-488-conjugated goat anti-
mouse and anti-rabbit antibodies and 4',6-diiamino-2-phenylindole
dihydrochloride (DAPI) were from Molecular Probes (Carlsbad, CA).
Horseradish peroxidase (HRP)-conjugated anti-mouse antibodies
(1:10,000) were obtained from Promega (Madison, WI). Horseradish
peroxidase (HRP)-conjugated anti-rabbit antibodies (1:20,000) were
obtained from Zymed (San Francisco, CA).
2.2. Plasmids
DNA encoding murine (m)VDAC1 (obtained from W.J. Craigen,
University of Houston) or N-terminally truncated mVDAC1 (Δ(26)
mVDAC1) was cloned into the pcDNA4/TO vector to allow for
tetracycline-regulated expression, as described previously [3].
Plasmids encoding the fusion proteins, rVDAC1-GFP2 and rVDAC1-
Rluc were constructed using the BRET2 plasmids (Perkin Elmer,
Waltham, MA). The rVDAC1 gene was cloned into BamHI and HindIII
sites of the BRET2 plasmids encoding luciferase (RLuc) or GFP2 (N2
variant) and ampliﬁed using the followingprimers: forward: CGAAGCT-
TATGGCTGTGCACCCACGT-ATGCC and reverse primer: GGATCCGCCG-
CCGCCGGAGCCGCCGCCGCCTGCTTGAAA-TTC. The reverse primer was
designed to include a double linker sequence encoding three glycines
and one serine ((GGGS)2) connecting the rVDAC1 and RLuc or GFP2
genes, to allow ﬂexibility of the region [37].
Plasmids encoding shRNA against human VDAC1 (hVDAC1) for
speciﬁc silencing of endogenous human (h)VDAC1 were generated
using a shRNA-expressing vector. The hVDAC1-shRNA-encoding se-
quence was created using the two complimentary oligonucleotides
indicated below, each containing the 19 nucleotide target sequence of
hVDAC1 (337–355), followed by a short spacer and an anti-sense
sequence directed against the target: oligonucleotide 1, AGCTTAA-
AAACACTAGGCACCGAGATTATCTCTTGAATAATCTCGGTGCCTAGTGTG
and oligonucleotide 2, GATCCACACTAGGCACCGAGATTATTCAAGAGA-
TAATCTCGG TGCCTAGTGTTTTTTA. The hVDAC1-shRNA-encoding se-
quence was cloned into the BglII and HindIII sites of the pSUPERretro
plasmid (OligoEngine, Seattle, WA), containing a puromycin-
resistance gene. Transcription of this sequence under the control
of the H1 RNA promoter of RNA Polymerase III produces a hairpin
(hVDAC1-shRNA).
2.3. Tissue culture
T-REx-293 cells (HEK cells stably containing the pcDNA4/TO
regulatory vector containing the tetracycline repressor; Invitrogen)
and T-REx-293 cells stably expressing hVDAC1-shRNA, showing low
(10–20%) endogenous hVDAC1 expression (referred to as T-REx-
pS10), were grown at 37 °C under an atmosphere of 95% air and 5%
CO2 in DMEM supplemented with 10% FCS, 2 mM L-glutamine,
1000 U/ml penicillin, 1 mg/ml streptomycin, 5 μg/ml blasticidin
and 0.5 μg/ml puromycin (only for T-REx-pS10 cells). MCF7 and
HeLa cell line were grown under the same conditions as were T-REx-
293 cells, except that blasticidin was not added.
2.4. Cell transfection
T-REx-293 cells at ∼40% conﬂuency were transiently transfected
(using metafecene) with plasmids pcDNA4/TO encoding rVDAC1,
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Protein expression was induced by tetracycline (2.5 μg/ml) for 72–
110 h before the cells were subjected to apoptosis induction and
cross-linking analysis.
For BRET experiments, T-REX-pS10 cells were transfected using
the calcium phosphate method. Transfections were carried out with
0.2 of a plasmid encoding for rVDAC1-Rluc and with 0.8 µg of a
plasmid encoding for rVDAC1–GFP2, respectively (BRET2 cells). Cells
were analyzed for induction of apoptosis and BRET2 48 to 72 h post-
transfection. As a negative control, cells were transfected with plas-
mids encoding for rVDAC1-Rluc (0.2 µg DNA) and GFP2 (0.8 µg). As an
additional control (control cells), cells were transfected with plasmids
encoding for rVDAC1-Rluc (0.2 µg) and pcDNA4/TO (0.8 µg).
2.5. BRET assay
Cells transiently expressing rVDAC1-Rluc and rVDAC1-GFP2, as
well as control cells, were incubated with an apoptosis inducer. The
cells were then harvested, washed twice with PBS, resuspended in
200 µl of PBS and divided between two wells of a 96-well white clear-
bottom plate (Grenier). Luciferase activity was initiated by the
addition of the membrane-permeable substrate, coelentrazine (Deep-
BlueC (DBC), to a ﬁnal concentration of 5 µM to cells in PBS supple-
mented with MgCl2 (1 g/L) and glucose (1 g/L). DBC was added just
before luminescence measurement. All measurements were per-
formed using the Inﬁnite 200 (Tecan) ELISA reader.
The BRET2 signal represents the ratio of the GFP2 ﬂuorescence
measured at its emission wavelength (510 nm) over the light in-
tensity (luminescence) emitted at 395 nm. The appropriate condi-
tions for resolving VDAC1 oligomerization using BRET2 in living
mammalian cells were determined previously (23). BRET2 signals,
deﬁned as GFP2/RLuc intensity ratio, were calculated as follows:
(a) The GFP2 ﬂuorescence obtained in VDAC1-Rluc/pcDNA4/To
cells (control cells) was subtracted from the GFP2 ﬂuorescence
obtained in cells expressing rVDAC1-Rluc and rVDAC1-GFP2
(BRET2 cells).
(b) The ratio of Renilla luciferase luminescent to net GFP2 ﬂuo-
rescence (i.e. GFP2 ﬂuorescence after subtraction of the GFP2
ﬂuorescence of the control cells) was calculated.
(c) The ratios of BRET2 signals between different cells exposed or
not exposed to the apoptosis inducers were compared.
2.6. Chemical cross-linking experiments
T-REx-293 or HeLa cells were exposed to STS (0.8 μM for 2.5 h),
H2O2 (1 mM for 4 h) or to sodium selenite (8 μM for 18 h) and then
harvested. The cells (2.5-3 mg/ml in PBS, pH 8.3) were incubated at
30 °C for 15 min with EGS or DFDNB for 30 min. Cross-linking was
terminated by addition of sample buffer and heating at 70 °C for
10 min. Cells were then sonicated and subjected to SDS-PAGE and
immunoblotting using anti-VDAC antibodies.
2.7. Apoptotic cell analysis
For propidium iodide (PI) and Annexin V-FITC staining, HeLa
cells (2–4×106) were exposed to an apoptosis inducer, collected
(1500 g×5 min), washed and resuspended in 195 µl binding buffer
(10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl and 2.5 mM CaCl2).
Annexin V-FITC (5 µl) was added to the cells for 15 min incubation in
the dark. Cells were then twice washed with and resuspended in
200 µl binding buffer, to which PI was added immediately before
analysis with an ImageSteam multi-spectral imaging ﬂow cytometer
(Amnis, Seattle, WA). At least 2000 images were collected for each
sample and images were divided into four sub-groups: live cells
(unstained), cells at early apoptotic state (stained with Annexin V-FITC), cells at late apoptotic state (stained by both Annexin V-FITC
and PI) and necrotic cells (stained with PI). Debris was eliminated
from the data.
2.8. Cytochrome c, Smac/Diablo and AIF release assayed by
immunoblot analysis
Release of Cyto c, AIF and Smac/Diablo from mitochondria to the
cytosol was measured by immunoblot. Cells were exposed to selenite,
staurosporine and DIDS, or AzRu [38]. Cells were harvested, washed
twice with PBS and gently resuspend at 6 mg/ml in ice-cold buffer
(100 mM KCl, 2.5 mM MgCl2, 250 mM sucrose, 20 mM HEPES/KOH
pH 7.5, 0.2 mM EDTA, 1 mMdithiothreitol, 1 μg/ml leupeptin, 5 μg/ml
cytochalasin B and 0.1 mMphenylmethylsulfonyl ﬂuoride) containing
0.025% digitonin and incubated 10 min on ice. Samples were
centrifuged at 10,000g at 4 °C for 5 min to obtain the supernatants
(cytosolic extracts free of mitochondria) and the pellets (fraction that
contains mitochondria). The supernatants were analyzed by SDS-
PAGE and immunoprobed using anti-Cyto c (1:2000, Cat #556433),
anti-Smac/Diablo (1:400) or anti-AIF (1:10,000) antibodies and then
with secondary horseradish peroxidase (HRP)-conjugated anti-
mouse or anti-rabbit IgG antibodies.
For immunocytochemistry, cells (4.5×105) were grown on PDL-
coated coverslips in 60 mm culture plates. After 48 h, the cells were
treated with DIDS (200 or 500 μM, 1 h) and with selenite (30 μM 3 h),
STS (0.7 μM 4 h), or cisplatin (50 μM, 30 h), ﬁxed for 15 min with 4%
paraformaldehyde, rinsed three times with PBS, treated with cold
methanol (−20 °C) for 10 min and rinsed with PBS. Next, the cells
were incubated for 1 h with blocking solution (5% normal goat serum
(NGS) and 0.1% Triton X-100 in PBS), followed by incubation with
anti-Cyto c (1:300, Cat #556432) or anti-AIF (1:300) antibodies
(diluted in blocking solution) for 2 h. After washingwith PBS, the cells
were incubated for 1 h with Alexa Fluor-488-conjugated antibodies
and washed with PBS. To stain nuclei, cells were incubated with DAPI
(0.07 μg/ml) for 5 min at room temperature and washed with PBS.
Coverslips were mounted on glass slides with mounting medium and
sealed with nail polish. Cells were visualized by confocal microscopy
(Olympus 1X81).
2.9. Gel electrophoresis and immunoblot analysis
Following SDS-PAGE (10 or 12% acrylamide), gels were stained
with Coomassie Brilliant blue or for immunostaining, electro-
transferred to nitrocellulose membranes. We found that the intensity
of the cross-linked VDAC antibody-labeled protein bands was highly
increased following treatment of the blot with acidic pH conditions
(0.1 M glycine, pH 2.2–4.0). Therefore, in all subsequent experiments,
such treatment was performed prior to immunoblotting. The protein-
containing membranes were incubated with blocking solution
containing 5% non-fat dry milk and 0.1% Tween-20 in Tris buffered-
saline, followed by incubation with monoclonal anti-VDAC
(1:10,000), anti-Cyto c (1: 2000, Cat #556433), polyclonal anti-AIF
(1:10,000), anti-Smac (1:400) or anti-actin (1:10,000) antibodies.
Membranes were then incubated with HRP-conjugated anti-mouse
IgG (1:10,000) or anti-rabbit IgG (1:20,000), as secondary antibodies.
Antibody binding was detected using an enhanced chemiluminescent
substrate (Beit Haemek) for detection of HRP.
3. Results
3.1. VDAC1 oligomerization is coupled to apoptosis
To obtain information on the oligomeric status of VDAC under
apoptotic conditions, we used chemical cross-linking with the mem-
brane-permeable cross-linker, EGSorDFNDB, andBRET2assay. Cellswere
ﬁrst exposed to the apoptosis inducers, STS or H2O2, and then incubated
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length, 16 Å) or DFDNB (space-arm length, 3 Å). VDAC oligomeric states
were then assessed by SDS-PAGE and immunoblotting, using anti-VDAC
antibodies (Fig. 1). The formation of VDAC homo-oligomers, comprising
dimers to higher molecular mass complexes, was enhanced several fold
upon exposure to STS (Fig. 1A) or H2O2 (Fig. 1D). Distinct anti-VDAC
antibody-labeledproteinbands (68, 99and136 kDa)wereobtainedupon
treatmentof the cellswitheither theEGSorDFDNBcross-linking reagents
(Fig. 1A and D), consistent with the presence of dimers, trimers and
tetramers. However, treatment with DFDNB yielded another anti-VDAC
antibody-reactive band of 79 kDa with a mobility slower than that of the
VDAC dimer in SDS-PAGE, andwhichwas obtainedwith andwithout STS
treatment (Fig. 1A). This band was not, however, obtained upon DFDNB
cross-linking of isolated mitochondria (Fig. 1B). This 79 kDa band may
represent a VDAC dimer with intermolecular cross-linking that modiﬁed
its mobility in SDS-PAGE or VDAC cross-linkedwith another unidentiﬁed
protein present in the cells but not in isolatedmitochondria preparations.
This putative additional protein, cannot be Bax, adenine nucleotide
translocase (ANT) or Bcl2, all shown to interact with VDAC, since it was
not identiﬁed by anti-ANT, anti-Bax or anti-Bcl2 antibodies (data not
shown). Finally, the same VDAC cross-linked products, i.e. dimers to
tetramers and multimers, were obtained with EGS-cross-linked cells
(Fig. 1A and D) and isolated mitochondria (Fig. 1B and E) and found to
containVDACbutnot otherprotein(s) [22]. As expected, STShadnoeffect
on VDAC oligomerization in isolated mitochondria (Fig. 1E).Fig. 1. Apoptosis induction triggers VDAC oligomerization. T-Rex-293 cells were exposed
incubated (3 mg/ml) at 30 °C with the indicated concentration of EGS for 15 min or with DFD
using anti-VDAC antibodies (A) or Coomassie staining (C). Rat liver mitochondria (RLM)
additional band, indicated by an arrow above the dimer, appeared upon DFDNB treatment in
apoptosis-inducing reagent, H2O2 (1 mM, 4 h), and the oligomeric status of the protein (D) w
STS (0.4 µM, 30 min) and then subjected to cross-linking with EGS, followed by immunoblott
trimers, tetramers and multimers are indicated. The positions of molecular weight proteinThe mild conditions used for cross-linking of VDAC are reﬂected
by the Coomassie-stained proﬁle of the cross-linked cells (Fig. 1C),
which revealed that only a minor degree of protein cross-linking was
obtained overall in the EGS-treated cells.
Not only STS and H2O2 (Fig. 1) but also other reagents, such as
selenite (Fig. 2), induced VDAC oligomerization, as revealed by EGS-
based cross-linking and immunoblotting using anti-VDAC antibodies.
Selenite has been recently shown to induce apoptosis in a VDAC-
dependentmanner [39]. Selenite treatment induced the appearance of
homo-dimers, trimers and tetramers of VDAC, as well as high-
molecular weight complexes. Indeed, VDAC oligomerization was
dramatically increased (up to 26-fold) upon exposure to selenite
(Fig. 2A).
The activity of selenite in terms of inducing apoptosis was analyzed
by following Annexin V-FITC labeling of surface apoptosis-induced
phosphatidylserine (PS) exposure (reﬂecting the early apoptotic state),
and propidium iodide (PI) staining of nuclear condensation and
fragmentation (reﬂecting the late apoptotic state), using ImageStream
multispectral imaging ﬂow cytometry (Fig. 2B) [40]. This morphology-
based method is used for accurate quantitation of apoptosis based on
nuclear condensation, nuclear fragmentation, and membrane blebbing
using automated image analysis on large numbers of images, as
collected in ﬂow by the ImageStreammultispectral imaging cytometer.
Images showing live cells, cells at the early apoptotic state (as stained
with Annexin V-FITC), cells at late apoptotic state (as stained by bothto the apoptosis-inducing reagent, STS (1.25 µM, 2.5 h), washed twice with PBS and
NB for 30 min. The cells were then subjected to SDS-PAGE, followed by immunoblotting
(1 mg/ml) were incubated with EGS or DFDNB, followed by immunostaining (B). An
cells (A) but not in isolated mitochondria (B). T-Rex-293 cells were also exposed to the
as analyzed as described above. Rat liver mitochondria (1 mg/ml) were incubated with
ing using anti-VDAC antibodies (E) or Coomassie staining (F). VDACmonomers, dimers,
standards are provided. R.U. indicates relative units.
Fig. 2. VDAC1 oligomerization and apoptosis induction. (A) Selenite-induced VDAC oligomerization was revealed by EGS-cross-linking of HeLa cells before and after 18 h of
incubation with selenite (8 μM). Cells (2.5 mg/ml) were washed twice with PBS and incubated with EGS (250 μM) at 30 °C for 15 min, followed by SDS-PAGE and immunoblotting
using monoclonal anti-VDAC antibodies and quantitative analysis. (B and C) HeLa cells were treated with 8 μM selenite for 18 h and apoptosis in cells stained with FITC-Annexin V
and PI was analyzed using an ImageStream multispectral imaging ﬂow cytometer, showing staining with Annexin V-FITC and nuclear condensation and fragmentation, as revealed
by PI staining (seeMaterials andmethods). Images of non-apoptotic, early apoptotic cells stained with Annexin V-FITC and late apoptotic cells, as stained with Annexin V-FITC and PI,
as well as necrotic cells stained with PI are shown in (B). Quantitative analysis of these cell types is presented in (C).
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with PI)were obtained (Fig. 2B). Quantiﬁcation of apoptosiswas carried
out by analysis of such cell images from a large numbers of collectedFig. 3. Apoptosis induction by STS or selenite is associated with VDAC oligomerization, as
luciferase (Luc) (light-producing enzyme) as the donor and VDAC1-GFP2 (ﬂuorophore) as
BRET signal is obtained when the two VDAC1molecules interact physically. (B) The ratios of t
or with the relevant amount of DMSO for 3 h are given. The shRNA-VDAC1 T-REx-293 ce
plasmids. As control, cells were co-transfected with the VDAC1-Rluc-encoding plasmid and a
or pcDNA4/TO. Luciferase and GFP signals were measured following 48 h of transfection. BR
activity was measured as luminescence while GFP ﬂuorescence was measured at 510 nm. Aimages (Fig. 2C). The results show that selenite (at the concentration
used) induced VDAC oligomerizationwhenmost cells (85%)were in the
early apoptotic state.revealed by BRET2. (A) Schematic representation of energy transfer between VDAC1-
the acceptor that occurs only when the donor and the acceptor are spatially close. The
he BRET2 signals obtained in cells treated with of STS (0.8 μM, 3 h), selenite (8 μM, 16 h)
lls were co-transfected with VDAC-Rluc (0.2 μg) and rVDAC1–GFP2-encoding (0.8 μg)
plasmid carrying only the GFP2 gene, as well as with plasmids encoding for VDAC1-Rluc
ET2 signals were calculated as described in Materials and methods section. Luciferase
ll readings were performed with an Inﬁnite 200 ELISA reader.
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in the membranes of living cells, the bioluminescence resonance
energy transfer (BRET2) assay [36] was performed on cells expressing
rVDAC1-Rluc as donor and rVDAC1-GFP2 as acceptor. This technique
is based upon energy transfer between the bioluminescent Renilla
luciferase (RLuc) reaction product and a variant of GFP (GFP2). Upon
substrate oxidation, RLuc releases an initial photon at a wavelength
compatible with the excitation wavelength of GFP2 [41,42]. The light
emitted due to Rluc oxidation of its substrate, DeepBlueC, can be
absorbed by GFP2, which subsequently ﬂuorescenes only if the two
molecules are very close (i.e. b 10 nm). Thus, BRET signal enhance-
ment resulting from interaction between rVDAC1-Rluc and rVDAC1-
GFP2 upon exposure to apoptosis inducers corresponds to an
activation of VDAC oligomerization, while attenuation of the BRET2
signal indicates inhibition of VDAC oligomerization (Fig. 3A).
rVDAC1-GFP2 and rVDAC1-Rluc were expressed in stably shRNA-
hVDAC-expressing T-REx-293 cells with a low level of endogenous
hVDAC. shRNA-VDAC1, being speciﬁc to human VDAC1, allows the
expression of rat (r)VDAC1 and decreases the participation of
endogenous hVDAC in VDAC oligomerization, thereby enhancing the
BRET2 signal. As shown (Fig. 3B), the well-deﬁned apoptosis inducers,
STS and sodium selenite, enhanced the BRET2 signal (GFP2/Rluc
ratio) in rVDAC1-Rluc- and rVDAC1-GFP2-expressing cells by 4- to 5-
fold, relative to the same cells not exposed to apoptosis inducer
(Fig. 3B). It should be noted that this enhancement was characteristicFig. 4. RuR and HK-I inhibit Cyto c, Smac/Diablo and AIF release as induced by cisplatin, or ST
to express native, E72Q-mVDAC1 or Δ(26)mVDAC1. 48 h post-transfection, the cells were ex
or AIF released into the cytosol were analyzed by immunoblotting using anti-Cyto c, anti-Sm
were transfected to express HK-I, while T-REx-293 cells were transfected to express native or
or STS (1.25 μM, 3 h), and analyzed for Cyto c, Smac/Diablo and AIF release, as described in (
and transfected to express native or Δ(26)mVDAC1. 48 h post-transfection, the cells were tr
15 min), immuno-stained using anti-AIF and Alexa Fluor-488-conjugated antibodies and v
section is shown (bar=5 μm).only of rVDAC1-Rluc- and rVDAC1-GFP2-expressing cells, and did not
appear in cells transfected with rVDAC1–Rluc- and GFP2-encoding
plasmids (data not shown), thus verifying that BRET signal enhance-
ment reﬂects augmented VDAC oligomerization.
These results clearly demonstrate that exposing the cells to apopto-
sis inducers enhanced VDAC oligomerization, as reﬂected by both an
enhanced BRET2 signal and by chemical cross-linking-based assays.
3.2. Cells expressing Δ(26)VDAC1 do not release Cyto c, AIF or Samc/Diablo
In our recent study [3], the role of the VDAC1N-terminal domain in
regulating VDAC1 activity in cell life and apoptotic cell death was
investigated via the use of Δ(26)mVDAC1, an N-terminally truncated
form of murine VDAC1 expressed in human (h)VDAC1-shRNA cells
expressing low levels of endogenous VDAC1. It was found that cells
expressing Δ(26)mVDAC1 do not release Cyto c and are resistant to
apoptosis, as induced by various stimuli [3]. In addition, cells over-
expressing Δ(26)mVDAC1 were able to undergo oligomerization, as
revealed by chemical cross-linking. Moreover, it was also shown that
the VDAC1 N-terminal region plays a role in the proper function of the
protein during apoptotic events [44]. Thus, it appears that the N-
terminal region is not required for VDAC oligomerization but is
important for Cyto c release and subsequent apoptosis.
To verify whether the N-terminal region of VDAC1 is essential not
only for Cyto c release ([3], Fig. 4) but also for the release of AIF andS in cells expressing native but not Δ(26)mVDAC1. (A) T-REx-293 cells were transfected
posed to RuR (2 μM, 18 h) and then to STS (1.25 μM, 3 h). Levels of Cyto c, Smac/Diablo
ac/Diablo or anti-AIF antibodies, as described in Materials and methods. (B) MCF 7 cells
Δ(26)mVDAC1. 60 h post-transfection, the cells were exposed to cisplatin (50 μM, 30 h)
A). (C) T-REx-293 cells (5×104) were grown on PDL-coated coverslips in a 60 mm plate
eated with cisplatin (50 μM, 30 h), PBS–washed and ﬁxed with paraformaldehyde (4%,
isualized by confocal microscopy (bar=10 μm). (D) An enlargement of the indicated
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to cisplatin or STS and the release of AIF from the mitochondria was
analyzed by immunoblotting (Fig. 4A and B). The results show that
cisplatin and STS induced the release of AIF and Smac/Diablo in cells
expressing native but not in cells expressing Δ(26)mVDAC1, as
obtained with Cyto c release. Thus, the N-terminal region of VDAC1 is
required not only for the release of Cyto c but also for AIF and Smac/
Diablo release (Fig. 4A and B). It should be noted that AIF and Smac/
Diablo are present in the cytosol in untreated cells, yet upon apoptosis
induction, their levels were increased by about 7- to 10-fold (see
Fig. 4).
Further support for VDAC involvement in apoptotic signaling
inducing AIF and Smac/Diablo release is presented by the ﬁnding that
the VDAC-interacting compound that inhibits apoptosis, i.e. RuR [45–
52], inhibited not only Cyto c release as induced by STS or cisplatin
but also the release of AIF and Smac/Diablo (Fig. 4A). In addition, RuR-
mediated inhibition of Cyto c, AIF and Smac/Diablo release was
diminished in cells expressing the RuR-insensitive E72Q-mVDAC1
mutant (Fig. 4A).
Hexokinase expression inhibited not only Cyto c release as induced
by STS or cisplatin but also the release of AIF and Smac/Diablo in
either MCF7 or T-REx cells (Fig. 4B).
AIF activation can be followed by its translocation from the
mitochondria to the nucleus, as analyzed by immonocytochemistry
(Fig. 4C). In cells expressing native mVDAC1, the punctuated
mitochondrial localization of AIF was changed upon exposure to the
apoptosis stimulant, cisplatin, with AIF becoming associated with the
nucleus. No such change in AIF distributionwas, however, observed in
cells expressing Δ(26)mVDAC1 (Fig. 4C).
Next, we showed that DIDS [53,54] and AzRu [49], shown to
interact with VDAC and inhibit apoptosis, both inhibited STS- or
selenite-induced release of both Cyto c and AIF (Fig. 5A and B).
The effect of DIDS on selenite-induced Cyto c and AIF release is
illustrated in representative confocal images of cells treated with
DIDS or selenite (Fig. 5C). The mitochondrial distribution of Cyto c
was punctuated and become diffuse upon exposure to selenite. In
untreated cells, the mitochondrial localization of AIF was punctuated,
while upon exposure to selenite, it co-localized with DAPI staining,
namely associated with the nucleus. DIDS strongly inhibited such
change in AIF distribution (Fig. 5C). Similar results were obtained
with DIDS, inhibiting Cyto c and AIF release as induced by STS
(Fig. 5D). The inhibition by DIDS of STS- and selenite-induced Cyto c
and AIF release from the mitochondria to cytosol, and the transloca-
tion of AIF to the nuclei suggest that VDAC is involved in the release of
these molecules.
4. Discussion
In this study, the function of VDAC1 in apoptosis was addressed
using VDAC1 mutants and VDAC channel inhibitors. We have shown
that the N-terminal region of VDAC1 is required for the releases of
Cyto c, Smac/Diablo and AIF and thus for subsequent apoptotic cell
death. In addition, we have demonstrated that apoptosis induction is
associated with VDAC oligomerization.
4.1. VDAC1 oligomerization as a proposed mechanism for the release of
pro-apoptotic proteins
Our results suggest that under physiological conditions, VDAC
molecules are not frequently in close enough proximity to allow
EGS to cross-link the monomers to form oligomers. However, upon
apoptosis induction, VDAC molecules become associated to form
oligomeric complexes, possibly mediating the release of Cyto c, Smac/
Diablo and AIF. We have shown that all apoptosis inducers–
irrespective of their chemical formula and mechanism of action–
induced VDAC oligomerization, indicating a strong coupling betweenVDAC oligomerization and apoptosis induction [2,3,23,24] (Figs. 1 and
2). Furthermore, using the BRET2 assay, we demonstrated the
oligomerization of VDAC1 molecules in mitochondrial membranes
of living cells [23] (Fig. 3).
The existence of VDAC oligomers either in the mitochondria or as
the puriﬁed protein gained support not only from cross-linking
experiments (Fig. 1) [22,55] but also from the NMR-based studies
[19,27,28] and the recent description of the crystal packing of
mVDAC1, showing anti-parallel dimers that further assemble into
hexamers [29]. Indeed, oligomeric packing was observed in EM [30]
and AFM images of the OMM of yeast [26] and potato tubes [25].
However, the function of these VDAC oligomeric structures is still not
clear. We have shown that VDAC oligomerization is highly enhanced
upon apoptosis, as induced by various stimuli, and is directly
associated with Cyto c release (Figs. 1–3) [23,24]. The ﬁnding that
the apoptosis-inducing effect of As2O3 could be attributed to an
induction of VDAC homo-dimerization, which can be prevented by
Bcl-xL [56], or to the formation of Bax and VDAC hetero- and homo-
oligomers [57], supports the involvement of VDAC oligomerization in
apoptosis. Thus, we propose that apoptosis induction by various
apoptosis inducers leads to the formation of homo-oligomers and/or
hetero-oligomers containing VDAC1 and pro-apoptotic proteins,
serving as a protein-conducting channel, allowing Cyto c (and
possibly Smac/Diablo and AIF) release and subsequent apoptotic
cell death (see Fig. 6). Ultimately, however, multiple pathways and
mechanisms of Cyto c release can be activate, depending on the cell
type and the nature of the stimulus [34,35].
Intriguingly, oligomerization as a mechanism to mediate Cyto c
release and thus apoptosis has also been previously proposed for two
key proteins in the mitochondrial pathway of apoptosis, namely Bax
and Bak [58–60]. Indeed, cooperative oligomerization of Bax/Bak, as
encouraged by various apoptosis stimuli, was shown to facilitate
OMM permeability and cell death in some apoptotic models [58–60].
4.2. The N-terminal of VDAC1 is essential for Cyto c, Smac/Diablo and
AIF release and apoptosis induction
Our results suggest that not only VDAC oligomerization but also the
N-terminal region of VDAC1 is involved in the release of pro-apoptotic
proteins and apoptosis. We have demonstrated that cells expressing N-
terminally truncated VDAC1 are resistant to apoptosis, as induced by
various inducers [3,44]. Here, we show that the N-terminal of VDAC1 is
required not only for Cyto c release and subsequent apoptosis but also
for the release of AIF and Smac/Diablo (Fig. 4). Since N-terminally
truncatedVDAC1undergoes oligomerization [3],wepropose that theN-
terminal of VDAC1 is involved in converting the oligomeric VDAC1
complex to a protein-conducting channel. Considering the VDAC1
molecule as a β-barrel embedded within the bilayer, the oligomeric
complexmay constitute a hydrophobic pore. Sucha pore is not expected
to serve as a pathway for soluble and charged proteins, such as Cyto c.
Thus, upon receiving an apoptotic signal, the amphipathic α-helix N-
terminal regionmayundergo translocation to lay on theoligomeric pore
surface, generating a hydrophilic pore (see Fig. 6). Recently, the 3D
structures of recombinant human and murine VDAC1 were solved by
NMR spectroscopy and X-ray crystallography [19,27,61] and showed
that VDAC1 adopts a β-barrel architecture comprising 19 β-strands and
anα-helixN-terminal positionedwithin thepore.However, the location
of the N-terminal within the poremight not represent the physiological
state, as the proposed VDAC1 structure has been questioned [62]. In
addition, other approaches point to the N-terminal α-helix as being
exposed to the cytoplasm [44], as crossing the membrane [1] or laying
on themembrane surface [63].Moreover, other studies showed that the
N-terminal region of VDAC1 exhibits motion during voltage gating [64],
and in membrane-embedded VDAC1, the N-terminal region is exposed
to antibodies raised against this part of the protein [43,55,65]. These
ﬁndings are in accord with the N-terminal assuming multiple positions
Fig. 5. AzRu and DIDS inhibit Cyto c, and AIF release and AIF translocation to the nucleus, as induced by selenite or STS. (A) HeLa cells were grown 48 h and incubated with DIDS
(200 μM, 1 h) and then treated with selenite (30 μM, 3 h). Cells were harvested and incubated with digitonin, on ice for 10 min, centrifuged, and the supernatants were subjected to
SDS-PAGE and immunoblot, using anti-Cyto c or anti-AIF antibodies. (B) HeLa cells were grown 48 h and incubated with DIDS (100 μM, 1 h) or AzRu (5 μM 16 h) and then treated
with STS (0.9 μM, 2.5 h). Cyto c and AIF release was assayed as described in Fig. 4. (C) HeLa cells were grown 48 h and incubated with DIDS (500 μM, 1 h) and then treated with
selenite (30 μM, 3 h). (D) HeLa cells were grown 48 h and then treated with STS (0.7 μM, 4 h) or DIDS (200 μM, 1 h). Cells were subjected to immunocytochemical analysis of Cyto c
and AIF distribution using anti-Cyto c or anti-AIF antibodies and Alexa Fluor 488-conjugated anti-mouse or anti rabbit antibodies, respectively, as secondary antibodies. Nuclei were
stained with DAPI (blue). Scale bars=10 μm. (E) An enlargement of the indicated section is shown (bar=6.7 μm).
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has been shown to be a proteinmoiety essential for apoptosis induction
[3,44]. How diverse apoptotic stimuli converge to N-terminal motion is
not clear. Voltage changes across the OMM, phosphorylation or
oxidation state of VDAC may modulate the conformation of VDAC or
its N-terminal, resulting in relocation of the latter.In addition, we have shown that the N-terminal region of VDAC1 is
the target of apoptosis-regulating proteins [3,46,66]. N-terminal
region binding by apoptosis-regulating proteins of the Bcl2 family
(i.e. Bcl-xL) [67], Bcl2 and HK-I [3] may prevents mobility of this
VDAC1 domain and, therefore, prevent Cyto c release, in turn, pro-
tecting against apoptosis [3,46,66].
Fig. 6.Model for VDAC1-N-terminal region- and VDAC1 oligomerization-mediated cytochrome c, Smac/Diablo and AIF release. Schematic presentation of VDAC1 as a monomer or
dimer with the amphipathic α-helix N-terminal region cytoplasmically exposed, membrane-spanning, lying on the membrane surface, or positioned in the pore. Upon receiving an
apoptotic signal, VDAC is stimulated to form homo-oligomers with the amphipathic α-helix N-terminal region of each VDAC molecule ﬂipping inside the hydrophobic pore formed
by the β-barrels. This results in the formation of a hydrophilic pore capable of mediating Cyto c, Smac/Diablo and AIF release into the cytosol. Hetero-oligomers composed of both
VDAC1 and Bax are also proposed as a possible apoptogenic protein release pathway.
1289V. Shoshan-Barmatz et al. / Biochimica et Biophysica Acta 1797 (2010) 1281–12914.3. VDAC1 is involved in the release of AIF and Smac/Diablo
Currently the mechanism(s) and/or pathway(s) of release of
Smac/Diablo, HtrA2/Omi, and AIF are not clear. It has been shown
that AIF induces apoptosis in a caspase-independent manner, as this
process is not inhibited by the pan-caspase inhibitor, z-VAD-fmk [68].
Others, however, consider AIF release to occur downstream of Cyto c
release, as demonstrated by inhibition of AIF release in the presence of
caspase inhibitors [69,70]. It has been reported that Bax/Bak-
mediated mitochondrial permeabilization does not directly induce
AIF release and that AIF release occurs downstream of Cyto c release
[70]. Similarly, it was shown that the OMM permeabilization induced
by Bax-, tBid- or Bax/Bak-dependent pro-apoptotic drugs results in
the release of Cyto c, Smac/Diablo and HtrA2/Omi but that
subsequent caspase activation is required to induce the translocation
of EndoG and AIF into the cytosol [69]. It has also been shown that
formation of the permeability transition pore in mitochondria results
in the release of AIF and Cyto c [12]. Clearly, the mechanism(s) AIF
activation and release from its mitochondria location have not been
completely elucidated.
In our attempt to verify the function of VDAC in AIF and Smac/
Diablo release frommitochondria, we gathered evidence, through the
use of VDAC inhibitors and VDAC1mutants, supporting VDAC as being
involved not only in the release of Cyto c but also of AIF and Smac/
Diablo (Figs. 4 and 5) [71]. Reagents shown to interact with VDAC,
such as RuR [48,49], AzRu [72], DIDS [54] and HK [24,45–47,51,52], all
inhibited the release of Cyto c and AIF (Figs. 4 and 5). RuR was shown
to inhibit Cyto c release, activation of caspase 3 and curcumin-induced
apoptosis in the U-937 cell line [73]. RuR also inhibits both ursolic
acid-induced cell death in LH-60 cells [74] and microcystin-induced
cell death in cultured rat hepatocytes [75]. The mechanism by which
RuR protects against cell death has not yet been established. However,
RuR directly interacts with native but not certain VDAC1 mutants
(E72Q- or E202Q) to reduce channel conductance and to prevent
apoptosis [48,49,52]. It thus appears that RuR-mediated protection
against apoptosis induced by the various stimuli is exerted through its
direct interaction with VDAC. Accordingly, the ﬁnding that RuR
inhibited the release of AIF and Smac/Diablo (Fig. 4A) suggests the
involvement of VDAC1 in this release. This is further supported by the
inhibition of Smac/Diablo and AIF release by HK-I (Fig. 4B), which
mediates its anti-apoptotic effect via interaction with VDAC1 [45–
47,50–52]. In addition, it was found that DIDS, a VDAC channel [54]
and apoptosis inhibitor [4,23,76], and an inhibitor of VDAC oligomer-
ization [23], inhibited STS- or selenite-induced AIF release (Fig. 5) andinhibited curcumin-induced apoptosis, mitochondrial Bax transloca-
tion and release of AIF from mitochondria [71]. Furthermore, the
VDAC1 N-terminal α-helix, previously shown to be a critical
component in mitochondria-mediated apoptosis [3,44] and to
mediate the regulation of Cyto c release and apoptosis by HK-I and
Bcl2 [3,44,66], is now shown to be also required for the release of AIF
upon activation by STS or cisplatin (Fig. 4).
Recently, it has been shown that ERp57-associated mitochondrial
μ-calpain cleaves AIF to a truncated form, tAIF, while m-calpain
truncates VDAC in a Ca2+-dependent manner. The calpain inhibitor,
PD150606, and anti-VDAC and anti-Bax antibodies prevented the
release of tAIF from mitochondria, suggesting that the release of tAIF
could be controlled not only by mitochondrial μ-calpain but also by
VDAC and Bax [77]. Taken together, the results presented here and
those reported elsewhere strongly suggest the involvement of VDAC
in the release of Smac/Diablo and AIF. Clearly, further experiments
are required to determinate whether Smac/Diablo and AIF are re-
leased with or following Cyto c release and whether the same pore is
involved.
In summary, the results presented here further support the close
relationship between VDAC oligomerization and apoptosis induction
and point to the N-terminal of VDAC1 as being essential for the release
of Cyto c and possibly of Smac/Diablo and AIF. There are, however,
many outstanding questions yet to be answered with respect to
apoptosis signals, inducing VDAC oligomerization and the motion of
its N-terminal region, associated with Cyto c release and apoptosis.
These include further demonstration of VDAC oligomer architecture,
dynamics, mechanism of formation, signaling pathways triggering
VDAC oligomerization and more.
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